[HTML][HTML] Long-term prognostic value of the response to therapy assessed by laboratory and imaging findings in patients with differentiated thyroid cancer

M Klain, E Zampella, L Piscopo, F Volpe, M Manganelli… - Cancers, 2021 - mdpi.com
Simple Summary In patients with differentiated thyroid cancer (DTC), the American Thyroid
Association dynamic risk stratification system has been proposed to identify patients at …

Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer

S Ito, S Iwano, K Kato, S Naganawa - Annals of Nuclear Medicine, 2018 - Springer
Objective To identify prognostic factors associated with a low-iodine diet (LID) and the
amount of remnant thyroid tissue in Japanese patients with differentiated thyroid cancer …

The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I

FA Verburg, RBT Verkooijen… - Nuklearmedizin …, 2009 - thieme-connect.com
Objective: Dosimetry studies have shown that activities of 131 I as small as 10-20 MBq may
cause a stunning effect. A result of this stunning effect may be a lower success rate of the …

Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low‐risk well‐differentiated thyroid cancer

S Tsirona, V Vlassopoulou, M Tzanela… - Clinical …, 2014 - Wiley Online Library
Objective Postoperative radioiodine remnant ablation (RRA) represents an adjunctive
therapeutic modality in patients with differentiated thyroid cancer (DTC). The impact of late …

Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer

SM El-Refaei, SW Yassin, K Salman… - Nuclear Medicine …, 2015 - journals.lww.com
Aim The aim of this study was to assess ablation outcome after a second ablation dose and
compare the ablation rate after low and high reablation doses of iodine-131 (131 I) after …

[PDF][PDF] Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal

WJG Oyen, C Verhagen, E Saris… - Journal of Nuclear …, 2000 - Soc Nuclear Med
For differentiated, nonmedullarythyroid carcinoma, postsurgical ablationof thyroid
remnantsand treatmentof residualtumor and metastaseswith 1311is a …

Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan

M Chao - Clinical Oncology, 2010 - Elsevier
BACKGROUND: Differentiated thyroid carcinoma (DTC) with rising thyroglobulin (Tg) level
and negative radioiodine whole body scan results has been observed in follow-up studies …

[HTML][HTML] Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an …

L Giovanella, AM Avram, J Clerc, E Hindié… - European journal of …, 2018 - Springer
Currently a trend towards Bde-escalating^ the role of adjuvant iodine-131 (131I) in the
treatment of differentiated thyroid cancer can be observed in the community of clinical …

[HTML][HTML] Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level

C Nascimento, I Borget, A Al Ghuzlan… - Endocrine-Related …, 2011 - erc.bioscientifica.com
131 I is given in differentiated thyroid cancer (DTC) without taking into account thyroglobulin
(Tg) levels at the time of ablation, whereas 6–18 months later it is a major criterion for cure …

Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with …

M Toubeau, C Touzery, P Arveux… - Journal of Nuclear …, 2004 - Soc Nuclear Med
The aim of our study was to evaluate and compare in thyroid cancer patients the predictive
value for disease progression of thyroglobulin (Tg) levels measured under thyroid …